Business
Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2022
Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2022.
About this update from Avivagen, Inc.
[{"type":"text","content":"\nAvivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the Second quarter of 2022.\n\nSecond Quarter April 30, 2022, Financial Results\n\nThe Company’s unaudited Financial Statements for the second quarter ended April 30, 2022, and the accompanying Management’s Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are available via its website (www.sedar.com). The financial information for the second quarter ended April 30, 2022, should be read in conjunction with the Company’s unaudited Financial Statements as well as its Management’s Discussion and Analysis for the second quarter ended April 30, 2022\n\nThe Company reported net revenues of $88,438 (compared to $159,614 in the quarter ending April 30, 2021) and a comprehensive loss of $(1,303,677) for the quarter ending April 30, 2022. This compares to a comprehensive loss in the quarter ending April 30, 2021, of $(2,197,649). As at April 30, 2022, the Company reported total assets of $3,013,537 (current assets of $2,878,566), total liabilities of $6,907,179, and shareholders’ deficit of ($3,893,642).\n\nAbout Avivagen\nAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.\n\nAbout OxC-beta™ Technology and OxC-beta™ Livestock\nAvivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provide...